文献速递心境障碍

预防性认知治疗联合抗抑郁药减量对比单用抗抑郁药维持治疗预防抑郁复发(DRD研究)

Effectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study): a three-group, multicentre, randomised controlled trial.
PubMed 文献 · Lancet Psychiatry · 2018-04-03

该多中心三组随机对照试验纳入289例至少两次抑郁发作且经抗抑郁药治疗缓解或恢复的个体,比较单用抗抑郁药、预防性认知治疗联合抗抑郁药减量、预防性认知治疗联合抗抑郁药三种策略预防复发效果。结果显示单用抗抑郁药不优于预防性认知治疗联合减量,而预防性认知治疗联合抗抑郁药较单用抗抑郁药降低41%相对复发风险。

要点

  • 对反复抑郁发作且希望停药者,可考虑预防性认知治疗联合减量策略。

核心结论

  • 维持抗抑郁药治疗在恢复后不优于预防性认知治疗,而预防性认知治疗联合抗抑郁药优于单用抗抑郁药。
  • 预防性认知治疗应提供给正在使用抗抑郁药的反复抑郁个体以及希望恢复后停药者。

研究设计与样本

  • 单盲、多中心、平行三组随机对照试验,按10:10:8随机分配至预防性认知治疗联合抗抑郁药、单用抗抑郁药、预防性认知治疗联合抗抑郁药减量。
  • 纳入289例至少两次抑郁发作且经抗抑郁药治疗至少6个月处于缓解或恢复期的个体,主要结局为意向性治疗人群中24个月内抑郁复发或再发的时点相关比例。

主要发现

  • 24个月随访期间发生2例自杀未遂(单用抗抑郁药组1例,预防性认知治疗联合减量组1例)和1例死亡(预防性认知治疗联合抗抑郁药组),均与干预无关。

关键数值与推荐

  • 纳入标准:既往至少两次抑郁发作,经抗抑郁药治疗至少6个月处于缓解或恢复期。
  • 排除标准:当前躁狂或轻躁狂、双相障碍史、精神病史、当前酒精或药物滥用、需治疗的焦虑障碍、每月心理治疗超过两次、器质性脑损伤诊断。

临床怎么用

  • 对反复抑郁发作且正在使用抗抑郁药的个体,可提供预防性认知治疗以增强维持治疗疗效。
  • 对希望恢复后停用抗抑郁药的个体,可提供预防性认知治疗联合减量策略。
  • 单用抗抑郁药维持治疗不优于预防性认知治疗联合减量,临床决策需结合患者意愿。

局限性

  • 单盲设计,医生和参与者无法设盲,评估者设盲。
  • 样本量289例,随机分配比例为10:10:8,各组样本量不均。
  • 随访24个月,评估4次,长期效果未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Keeping individuals on antidepressants after remission or recovery of major depressive disorder is a common strategy to prevent relapse or recurrence. Preventive cognitive therapy (PCT) has been proposed as an alternative to maintenance antidepressant treatment, but whether its addition would allow tapering of antidepressants or enhance the efficacy of maintenance antidepressant treatment is unclear. We aimed to compare the effectiveness of antidepressants alone, with PCT while tapering off antidepressants, or PCT added to antidepressants in the prevention of relapse and recurrence. METHODS: In this single-blind, multicentre, parallel, three-group, randomised controlled trial, individuals recruited by general practitioners, pharmacists, secondary mental health care, or media were randomly assigned (10:10:8) to PCT and antidepressants, antidepressants alone, or PCT with tapering of antidepressants, using computer-generated randomised allocation stratified for number of previous depressive episodes and type of care. Eligible participants had previously experienced at least two depressive episodes and were in remission or recovery on antidepressants, which they had been receiving for at least the past 6 months. Exclusion criteria were current mania or hypomania, a history of bipolar disorder, any history of psychosis, current alcohol or drug abuse, an anxiety disorder that requires treatment, psychological treatment more than twice a month, and a diagnosis of organic brain damage. The primary outcome was time-related proportion of individuals with depressive relapse or recurrence in the intention-to-treat population, assessed four times in 24 months. Assessors were masked to treatment allocation, whereas physicians and participants could not be masked. This trial is registered with the Netherlands Trial Register, number NTR1907. FINDINGS: Between July 14, 2009, and April 30, 2015, 2486 participants were assessed for eligibility and 289 were randomly assigned to PCT and antidepressant (n=104), antidepressant alone (n=100), or PCT with tapering of antidepressant (n=85). The overall log-rank test was significant (p=0·014). Antidepressants alone were not superior to PCT while tapering off antidepressants in terms of the risk of relapse or recurrence (hazard ratio [HR] 0·86, 95% CI 0·56-1·32; p=0·502). Adding PCT to antidepressant treatment resulted in a 41% relative risk reduction compared with antidepressants alone (0·59, 0·38-0·94; p=0·026). There were two suicide attempts (one in the antidepressants alone group and one in the PCT with tapering of antidepressants group) and one death (in the PCT and antidepressants group) not related to the interventions during the 24 months' follow-up. INTERPRETATION: Maintenance antidepressant treatment is not superior to PCT after recovery, whereas adding PCT to antidepressant treatment after recovery is superior to antidepressants alone. PCT should be offered to recurrently depressed individuals on antidepressants and to individuals who wish to stop antidepressants after recovery. FUNDING: The Netherlands Organisation for Health Research and Development.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bockting CLH, Klein NS, Elgersma HJ, et al. Effectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study): a three-group, multicentre, randomised controlled trial. Lancet Psychiatry. 2018. PMID: 29625762. doi:10.1016/S2215-0366(18)30100-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。